Natco Pharma Limited has completed the acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, a leading South African pharmaceutical company, for approximately USD 226 million (ZAR 4 billion). This major deal marks a strategic expansion for Natco Pharma, reinforcing its international growth ambitions and strengthening its position in the African market.
Contents
Acquisition Details
- Natco Pharma finalized the delisting of Adcock Ingram from the Johannesburg Stock Exchange (JSE), following a shareholder-approved offer of ZAR 75 (USD 4.36) per share made to Adcock Ingram’s minority shareholders in July 2025.
- The proposal received strong support from shareholders and was approved in October 2025, leading to the successful completion of the stake acquisition in November 2025.
- By acquiring a controlling stake, Natco gains greater influence and a direct operational presence in South Africa, one of the continent’s largest and most dynamic pharmaceutical markets.
Strategic Rationale
Natco Pharma aims to leverage Adcock Ingram’s well-established brand, market reach, and consumer trust to expand its portfolio and strengthen its healthcare impact across South Africa and other African countries. With this acquisition, Natco will:
- Broaden its product offerings by introducing innovative formulations and expanding the range available to African consumers.
- Enhance Adcock Ingram’s operational capabilities, boosting efficiency and accelerating access to high-value medicines in key therapeutic areas, notably oncology, cardiology, and neurology.
- Pursue further growth opportunities, partnerships, and expansion within the African region, building on the legacy and market foundation that Adcock Ingram represents.
Leadership Statement
Rajeev Nannapaneni, CEO of Natco Pharma, commented:
“This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond.”.
About the Companies
- Natco Pharma Limited is a public limited company listed on the Bombay Stock Exchange and National Stock Exchange of India, with a market capitalization around USD 2 billion. Founded in 1981, Natco Pharma has grown into a diversified manufacturer with operations in over 50 countries, focusing on research, development, manufacturing, and global marketing of finished dosage formulations and active pharmaceutical ingredients (APIs).
- Adcock Ingram is one of South Africa’s oldest pharmaceutical companies, known for its comprehensive healthcare product range and deep-rooted trust with consumers throughout South Africa.
Related Industry News
Natco Pharma recently received approval from the Supreme Court of India to launch generic Risdiplam at 80% lower price, following the dismissal of Roche’s appeal.
